Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Authors

Keywords

Journal

Volume 19, Issue 4, Pages 521-536

Publisher

Elsevier BV

Online

2018-03-13

DOI

10.1016/s1470-2045(18)30144-x

Discuss science. Find collaborators. Network.

Join a conversation

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now